Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + n-acetylcysteine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of metformin and N-acetylcysteine (NAC) that has been studied for its potential therapeutic effects in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and polycystic ovary syndrome (PCOS). Metformin improves insulin sensitivity and reduces hepatic glucose production, while NAC acts as an antioxidant that replenishes glutathione stores and reduces oxidative stress. The combination appears to have synergistic effects on metabolic parameters, particularly in improving liver histology and biochemical markers.
- Other names
- n-acetyl cysteine + metforminNAC + metforminN-acetylcysteine + metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)GSH (Glutathione)Misfolded SOD1
Beyond the preview
Go deeper on metformin + n-acetylcysteine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + n-acetylcysteine.